ZOMETA

Compare ZOMETA  to:
Compare
Compare

Generic Name for ZOMETA

Zoledronic acid 4 mg/vial; conc soln for IV infusion after dilution.

Legal Classification:

Rx

Pharmacological Class for ZOMETA

Bisphosphonate.

Manufacturer of ZOMETA

Novartis Pharmaceuticals Corp

Indications for ZOMETA

Hypercalcemia of malignancy. Adjunct in multiple myeloma and bone metastases of solid tumors.

Adult dose for ZOMETA

Give by IV infusion over at least 15 minutes. Hypercalcemia of malignancy (albumin-corrected serum calcium ≥12 mg/dL): max 4 mg; allow at least 7 days before retreating. Multiple myeloma or bone metastases: CrCl >60mL/min: 4 mg; CrCl 50–60mL/min: 3.5mg; CrCl 40–49mL/min: 3.3mg; CrCl 30–39mL/min: 3mg; CrCl <30mL/min: see literature; all: every 3–4 weeks (give oral multivitamin supplement with calcium 500 mg + Vit. D 400 IU daily).

Children's dosing for ZOMETA

Not recommended.

Contraindications for ZOMETA

Pregnancy (Cat.D).

Precautions for ZOMETA

Not recommended for use in patients with with bone metastases and severe renal impairment. Renal or hepatic insufficiency. Check serum creatinine before each dose: withhold until serum creatinine is within 10% of baseline if serum creatinine increases by 0.5 mg/dL from a normal pre-treatment level, or by 1 mg/dL from an abnormal pre-treatment level, within 2 weeks of next dose. Assure adequate hydration when treating hypercalcemia of malignancy. Closely monitor electrolytes (esp. calcium, magnesium, phosphate), CBC/differential, hematocrit, hemoglobin. Aspirin-sensitive asthma. Avoid dental surgery (do preventative dental work before therapy). Elderly. Nursing mothers: not recommended.

Interactions for ZOMETA

Additive hypocalcemic effect with aminoglycosides, loop diuretics. Caution with other nephrotoxic drugs (eg, thalidomide).

Adverse Reactions for ZOMETA

Fever, flu-like syndrome, GI upset, anemia, dyspnea, electrolyte disturbances, musculoskeletal pain (may be severe), hypotension, CNS effects, rigors, headache, paresthesia, renal toxicity; rare: jaw osteonecrosis.

How is ZOMETA supplied?

Vials—1

Related Disease:

Bone metastases
Hypercalcemia
Multiple myeloma
Neoplasms

Related Resources

FDA cancer drug approval rate reviewed in JNCI

February 19, 2010

The FDA's Office of Oncology Drug Products approved 53 new indications for the use of oncology and hematology drugs and biologics from July 2005 to the end of 2007.

Phase 3 study of perifosine for metastatic colon cancer

February 03, 2010

Æterna Zentaris and Keryx Biopharmaceuticals announced agreement with the FDA regarding a Special Protocol Assessment on its Phase 3 trial for perifosine (KRX-0401) for the treatment of refractory metastatic colorectal cancer.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Phase 3 trial of Tavocept for the treatment of lung adenocarcinoma

January 22, 2010

BioNumerik Pharmaceuticals announced the treatment of the first patients in their Phase 3 trial of Tavocept (BNP7787) for primary adenocarcinoma of the lung.

FDA approves addition of updated survival data and hepatic dosing to Velcade label

January 04, 2010

Millennium Pharmaceuticals announced that the FDA has approved an expanded label for Velcade (bortezomib) that includes long-term overall survival (OS) data from the VISTA trial as well as dosing recommendations for patients with hepatic impairment.